March 03, 2026 a 01:00 pm
ABBV: Fundamental Ratio Analysis - AbbVie Inc.
AbbVie Inc. is a leading pharmaceutical company with a diverse portfolio of drugs targeting various diseases. Despite facing challenges from biosimilar competition for its bestselling product HUMIRA, the company continues to invest in its robust pipeline and strategic collaborations. Its recent performance underscores steady growth, but investors should remain cautious of patent expiration risks.
Fundamental Rating
AbbVie's fundamental ratings reflect its solid cash flow management, though returns on equity and assets remain low. Its overall score suggests a need for cautious optimism.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 4 | |
| Return on Equity | 1 | |
| Return on Assets | 4 | |
| Debt to Equity | 1 | |
| Price to Earnings | 1 | |
| Price to Book | 1 |
Historical Rating
A comparison of historical ratings shows consistent scores, indicating stable, albeit cautious, performance in recent reviews.
| Date | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-03-02 | 2 | 4 | 1 | 4 | 1 | 1 | 1 |
| - | 0 | 4 | 1 | 4 | 1 | 1 | 1 |
Analyst Price Targets
Analysts remain optimistic about AbbVie's future performance, with a median target price suggesting potential for modest gains. However, the spread between high and low estimates emphasizes uncertainty.
| High | Low | Median | Consensus |
|---|---|---|---|
| $299 | $223 | $258 | $256.15 |
Analyst Sentiment
The prevailing analyst sentiment is bullish, favoring a "Buy" status. The ratings distribution highlights a lack of strong sell signals, suggesting substantive support for future value.
| Recommendation | Count | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 26 | |
| Hold | 12 | |
| Sell | 1 | |
| Strong Sell | 0 |
Conclusion
AbbVie Inc. presents a balanced investment case with a robust product portfolio and strong cash flow generation. The company's dependence on HUMIRA remains a vulnerability, but strategic investments in new drugs and collaborations could mitigate this risk. Analyst sentiments reinforce a positive outlook, though investors should remain vigilant of sector-specific dynamics. Overall, AbbVie offers potential growth tempered by near-term challenges, appealing to those with a moderate risk appetite.